Literature DB >> 19656893

Complementation of a herpes simplex virus ICP0 null mutant by varicella-zoster virus ORF61p.

Christos A Kyratsous1, Matthew S Walters, Christos A Panagiotidis, Saul J Silverstein.   

Abstract

The herpes simplex virus (HSV) ICP0 protein acts to overcome intrinsic cellular defenses that repress viral alpha gene expression. In that vein, viruses that have mutations in ICP0's RING finger or are deleted for the gene are sensitive to interferon, as they fail to direct degradation of promyelocytic leukemia protein (PML), a component of host nuclear domain 10s. While varicella-zoster virus is also insensitive to interferon, ORF61p, its ICP0 ortholog, failed to degrade PML. A recombinant virus with each coding region of the gene for ICP0 replaced with sequences encoding ORF61p was constructed. This virus was compared to an ICP0 deletion mutant and wild-type HSV. The recombinant degraded only Sp100 and not PML and grew to higher titers than its ICP0 null parental virus, but it was sensitive to interferon, like the virus from which it was derived. This analysis permitted us to compare the activities of ICP0 and ORF61p in identical backgrounds and revealed distinct biologic roles for these proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656893      PMCID: PMC2753114          DOI: 10.1128/JVI.01144-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Mutational analysis of the herpes simplex virus type 1 ICP0 C3HC4 zinc ring finger reveals a requirement for ICP0 in the expression of the essential alpha27 gene.

Authors:  E K Lium; S Silverstein
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Herpes simplex virus ICP0 mutants are hypersensitive to interferon.

Authors:  K L Mossman; H A Saffran; J R Smiley
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27.

Authors:  L A Samaniego; N Wu; N A DeLuca
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Repression of the alpha0 gene by ICP4 during a productive herpes simplex virus infection.

Authors:  E K Lium; C A Panagiotidis; X Wen; S Silverstein
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

5.  Modification of discrete nuclear domains induced by herpes simplex virus type 1 immediate early gene 1 product (ICP0).

Authors:  G G Maul; H H Guldner; J G Spivack
Journal:  J Gen Virol       Date:  1993-12       Impact factor: 3.891

6.  Promyelocytic leukemia protein mediates interferon-based anti-herpes simplex virus 1 effects.

Authors:  Ana V Chee; Pascal Lopez; Pier Paolo Pandolfi; Bernard Roizman
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

7.  Varicella-zoster virus (VZV) open reading frame 61 protein transactivates VZV gene promoters and enhances the infectivity of VZV DNA.

Authors:  H Moriuchi; M Moriuchi; S E Straus; J I Cohen
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

8.  An activity specified by the osteosarcoma line U2OS can substitute functionally for ICP0, a major regulatory protein of herpes simplex virus type 1.

Authors:  F Yao; P A Schaffer
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Herpes simplex viruses with mutations in the gene encoding ICP0 are defective in gene expression.

Authors:  J Chen; S Silverstein
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Varicella-zoster virus open reading frame 61 protein is functionally homologous to herpes simplex virus type 1 ICP0.

Authors:  H Moriuchi; M Moriuchi; H A Smith; S E Straus; J I Cohen
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

View more
  9 in total

1.  The RING finger domain of Varicella-Zoster virus ORF61p has E3 ubiquitin ligase activity that is essential for efficient autoubiquitination and dispersion of Sp100-containing nuclear bodies.

Authors:  Matthew S Walters; Christos A Kyratsous; Saul J Silverstein
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

2.  PML Body Component Sp100A Restricts Wild-Type Herpes Simplex Virus 1 Infection.

Authors:  Yilei Ma; Jingjing Li; Hongchang Dong; Zhaoxin Yang; Lingyue Zhou; Pei Xu
Journal:  J Virol       Date:  2022-03-30       Impact factor: 6.549

3.  Comparison of the biological and biochemical activities of several members of the alphaherpesvirus ICP0 family of proteins.

Authors:  Roger D Everett; Chris Boutell; Carol McNair; Louise Grant; Anne Orr
Journal:  J Virol       Date:  2010-01-27       Impact factor: 5.103

4.  Herpes simplex virus and varicella zoster virus, the house guests who never leave.

Authors:  Paul R Kinchington; Anthony J St Leger; Jean-Marc G Guedon; Robert L Hendricks
Journal:  Herpesviridae       Date:  2012-06-12

5.  Interplay between Herpesvirus Infection and Host Defense by PML Nuclear Bodies.

Authors:  Nina Tavalai; Thomas Stamminger
Journal:  Viruses       Date:  2009-12-15       Impact factor: 5.048

6.  Widely Used Herpes Simplex Virus 1 ICP0 Deletion Mutant Strain dl1403 and Its Derivative Viruses Do Not Express Glycoprotein C Due to a Secondary Mutation in the gC Gene.

Authors:  Cristina W Cunha; Kathryne E Taylor; Suzanne M Pritchard; Mark G Delboy; Tri Komala Sari; Hector C Aguilar; Karen L Mossman; Anthony V Nicola
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

Review 7.  The Fate of Speckled Protein 100 (Sp100) During Herpesviruses Infection.

Authors:  Mila Collados Rodríguez
Journal:  Front Cell Infect Microbiol       Date:  2021-02-01       Impact factor: 5.293

Review 8.  Interplay between viruses and host sumoylation pathways.

Authors:  Roger D Everett; Chris Boutell; Benjamin G Hale
Journal:  Nat Rev Microbiol       Date:  2013-04-29       Impact factor: 60.633

9.  Glycerosome of Melissa officinalis L. Essential Oil for Effective Anti-HSV Type 1.

Authors:  Giulia Vanti; Sotirios G Ntallis; Christos A Panagiotidis; Virginia Dourdouni; Christina Patsoura; Maria Camilla Bergonzi; Diamanto Lazari; Anna Rita Bilia
Journal:  Molecules       Date:  2020-07-08       Impact factor: 4.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.